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INTRODUCTION
Parietal thinning is defined as external thinning
of the parietal bone of the skull. The characteristic
site of parietal thinning is the posteromedial part of
the parietal bone (1-4). Two types of parietal thin-
ning have been described : flat and grooved (1,
4). The prevalence rate has been estimated to be
0.25-0.8% (4). Cederlund, et al. (1) showed that un-
equivocal parietal thinning was found in 86 (2.37%)
of 3636 consecutive patients, and that the male/fe-
male sex ratio was 1 : 1.9. Parietal thinning is more
common in women than men. At this time, the rea-
son for excessive bone resorption in the skull, es-
pecially in the posteromedial part of the parietal
bone in osteoporotic patients, remains unclear.
We studied the morphologic characteristics of the
skull and therapeutic effects of one-year alendro-
nate treatment on bone mineral metabolism in Japa-
nese osteoporotic patients with parietal thinning. Im-
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aging characteristics of the skulls of these patients
were visualized using modalities such as radiog-
raphy, three-dimensional computed tomography
(3D-CT), and technetium-99m methylenediphos-
phate (99mTc MDP) bone scintigraphy. Bone min-
eral metabolism was evaluated by urinary type I
collagen cross-linked N-telopeptides (NTX) and
serum bone-specific alkaline phosphatase (BAP).
Whole body and regional bone mineral density
(BMD) was measured by dual energy X-ray absorp-
tiometry (DXA).
Case 1.
A 74-year-old male was referred to us because of
a low BMD. His height was 159.5 cm and weight
45.0 kg. The body mass index (BMI) was 17.7 kg/
m2, indicating that he was thin. There was no past
history of fragile fracture.
Anteroposterior plain radiography revealed
asymmetric bilateral parietal thinning of the skull
(Fig. 1A). The lateral view of the plain radiograph
of the skull showed striking radiolucency at the con-
vexity of the parietal bones (Fig. 1B). 3D-CT and
coronal sectioning of the skull revealed asymmet-
ric external thinning of the posteromedial part of
the bilateral parietal bones and the disappearance
of diploe at the depressed area of the bilateral pa-
rietal bones (Fig. 1C-E). Anteroposterior and lat-
eral views of 99mTc MDP bone scintigraphy did not
show any changes in the parietal bone (Fig. 1F, G).
The mean BMD values of the 2nd to 4th lumbar
vertebrae (L2-4BMD), femoral BMD, whole body
BMD, and head BMD were measured by DXA us-
ing a Delphi densitometer (Hologic Inc., Waltham,
MA. USA) in array beam scanning mode. Regional
BMDs were measured for the head, upper extremi-
ties, lower extremities, ribs, thoracic spine, lumbar
spine and pelvis. L2-4BMD and femoral BMD of
this patient were low compared to the normal range,
indicating osteoporosis (Table 1).
The levels of serum BAP and urinary NTX were
high compared with normal ranges, indicating high
bone turnover and acceleration of bone resorption.
The level of serum alkaline phosphatase was high
compared to the normal range. The level of serum
intact PTH was within the normal range (Table 2).
The whole body BMD was increased, whereas
L2-4BMD, femoral neck BMD and head BMD
decreased after a one-year alendronte treatment
(Fig. 2A-D). Both urinary NTX and serum BAP in
case 1 decreased to normal ranges after one-year
alendronate treatment (Fig. 3A, B).
(A) (B) (C) (D)
(E) (F) (G)
Fig. 1. Imaging Diagnosis of Case 1.
Anteroposterior plain radiography revealed bilateral parietal thinning (white arrows) (A). Lateral view of the plain radiograph of the
skull showed an apparent radiolucent band at the convexity of the parietal bones (black arrow) (B). 3D-CT revealed asymmetric
thinning of the parietal bones (black and white arrows) (C, D). Coronal section at the level of the lesion showed asymmetric exter-
nal thinning of the bilateral parietal bones and the complete disappearance of diploe (white arrows) (E). Anteroposterior and lateral
views of 99mTc MDP bone scintigraphy did not show any changes in the parietal bones (F, G).
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(A) (B)
(C) (D)
Fig. 2. Regional and whole body BMDs before and after one-year alendronate treatment.
Whole body BMD of all patients increased after treatment (A). L2-4BMD of case 3 increased after one-year alendronate treatment. In
contrast, L2-4BMD of case 1 and 2 decreased (B). Femoral neck BMD of case 2 and 3 increased after treatment, whereas femoral neck
BMD of case 1 decreased (C). Head BMD of case 3 increased after treatment. In contrast, head BMD of case 1 and 2 decreased (D).
BMD, bone mineral density ; L2-4BMD, the mean BMD values of the 2nd to 4th lumbar vertebrae
(A) (B)
Fig. 3. Urinary NTX and serum BAP before and after one-year alendronate treatment.
Urinary NTX of all patients were high compared to the normal range. One-year alendronate treatment decreased the urinary NTX of
all three patients to normal levels (A). Serum BAP of case 1 and 2 were high compared to the normal range. In contrast, the serum
BAP of case 3 was within the normal range. One-year alendronate treatment decreased the serum BAP of case 1 and 2 to within the
normal range. The serum BAP of case 3 decreased compared to the pretreatment level of serum BAP (B).
Urinary NTX, urinary type I collagen cross-linked N-telopeptides ; Serum BAP, serum bone-specific alkaline phosphatase
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Case 2.
This case was a 73-year-old male. His height was
162.3 cm and weight 43.0 kg. The BMI was 16.4 kg/
m2, indicating that he was thin. There was past his-
tory of vertebral fractures of the thoracic and lum-
bar spine.
L2-4BMD and femoral BMD values were low com-
pared with normal ranges, indicating osteoporosis
(Table 1).
Plain radiography of the skull revealed asym-
metric and bilateral thinning of the parietal bones
(Fig. 4A). Lateral view of the plain radiograph of
the skull showed a radiolucent area at the convex-
ity of the parietal (Fig. 4B). 3D-CT and coronal sec-
tioning of the skull revealed asymmetric external
thinning of the posteromedial part of the bilateral
parietal bones and the disappearance of diploe at
the depressed area of the bilateral parietal bones
(Fig. 4C-E). The area of parietal thinning in the pa-
rietal bones of case 2 were greater that in the other
cases. Internal lamina seemed to be intact. The an-
teroposterior and lateral views of 99mTc MDP bone
scintigraphy did not show any changes in parietal
bone (Fig. 4F, G).
Levels of both urinary NTX and serum BAP for
Table 1. Bone mineral density (BMD) before one-year alen-
dronate treatment.
Case 1 Case 2 Case 3
L2-4 BMD (g/cm2) 0.632 0.583 0.729
TS -3.5 -3.9 -2.54
Femoral Neck BMD (g/cm2) 0.384 0.325 0.568
TS -3.6 -4.1 -2.01
Head BMD (g/cm2) 1.202 1.164 1.334
TS
Whole body BMD (g/cm2) 0.728 0.801 0.828
TS -3.25
L2-4 BMD, the mean BMD values of the 2nd to 4th lumbar
vertebrae ; TS, T score
There is no TS for Head BMD in Japan.
There is no TS for whole body BMD in males in Japan.
Table 2. Markers of bone mineral metabolism in the three
cases before one-year alendronate treatment.
Case1 Case 2 Case 3 Normal range
Serum Ca (mg/dl) 9.7 8.8 9.0 8.810.1
Serum P (mg/dl) 3.6 2.7 3.9 2.44.6
Serum AP (IU/l) 428 286 262 110354
Intact PTH (pg/ml) 23.2 28.0 32.0 1065
Serum BAP (U/l) 37.1 51.3 29.6 13.033.9
Urinary NTX (nMBCE/mM) 79.6 79.5 59.3 9.354.3
AP, alkaline phosphatatse ; PTH, parathyroid hormone ; BAP,
bone-specific alkaline phosphatase ; NTX, type I collage cross-
linked N-telopeptides
(A) (B) (C) (D)
(E) (F) (G)
Fig. 4. Imaging Diagnosis of Case 2.
Anteroposterior plain radiography revealed asymmetric parietal thinning (white arrows) (A). Lateral view of the plain radiograph of
the skull showed a radiolucent area at the convexity of the parietal bones (black arrow) (B). 3D-CT revealed asymmetric thinning of
parietal bones (black and white arrows) (C, D). Coronal section showed asymmetric external thinning of the bilateral parietal bone.
Diploe at the left parietal bone disappeared (E). Anteroposterior and lateral views of 99mTc MDP bone scintigraphy did not show any
changes in the parietal bone (F, G).
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case 2 were high compared to the normal ranges,
indicating high bone turnover and acceleration of
bone resorption. The level of serum intact PTH was
within the normal range (Table 2).
The whole body BMD and femoral neck BMD
increased, whereas the L2-4BMD and head BMD
decreased after one-year alendronate treatment
(Fig. 2A-D). Treatment decreased both urinary NTX
and serum BAP to normal ranges (Fig. 3A, B).
Case 3.
The patient was a 68-year-old female. Her height
was 146.8 cm and weight 47.2 kg. The BMI was
22.1 kg/m2. She was referred to us because of per-
sistent back pain. There was a past history of atrau-
matic vertebral fracture.
L2-4BMD and femoral BMD values were low
compared with the normal ranges, indicating os-
teopenia (Table 1).
Plain radiography of the skull revealed asymmet-
ric and bilateral flattening of the parietal bones
(Fig. 5A). Lateral view of the plain radiograph of
the skull showed no radiolucency at the convexity
of the parietal (Fig. 5B). 3D-CT and coronal sec-
tioning of the skull revealed the asymmetric exter-
nal thinning of the posteromedial part of the bilat-
eral parietal bones. The right parietal bone was thin-
ner than the left one (Fig. 5C-E). The anteroposte-
rior and lateral views of 99mTc MDP bone scintigra-
phy did not show any changes in parietal bone
(Fig. 5F, G).
The level of urinary NTX was high compared to
the normal range, indicating acceleration of bone
resorption. In contrast, the level of serum BAP was
within the normal range, indicating a normal level
of bone turnover. The level of serum intact PTH
was within the normal range (Table 2).
One-year alendronate treatment increased the
L2-4, whole body, femoral neck, and head BMD
(Fig. 2A-D). Urinary NTX decreased to the normal
range. Serum BAP was within the normal range,
and it decreased after treatment. (Fig. 3A, B).
(A) (B) (C) (D)
(E) (F) (G)
Fig. 5. Imaging Diagnosis of Case 3.
Anteroposterior plain radiography revealed bilateral parietal thinning (white arrows) (A). Lateral view of the plain radiograph of the
skull showed no radiolucency at the convexity of the parietal bones (B). 3D-CT revealed asymmetric thinning of the parietal bones
(black and white arrows) (C, D). The degree of thinning of the parietal bones on the right side was greater than that on the left side.
Coronal sectioning showed asymmetric external thinning of the parietal bones (E). The diploe at the right parietal bone disap-
peared. In contrast, the diploe at the left parietal bone was preserved (white arrows). Anteroposterior and lateral views of 99mTc
MDP bone scintigraphy did not show any changes in the parietal bone (F, G).
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DISCUSSION
External thinning of the posteromedial part of
the bilateral parietal bones is a morphological char-
acteristic of the skulls of osteoporotic patients with
parietal thinning. Previous studies (1, 4) have shown
that the most common site of parietal thinning is
the posteromedial part of the parietal bones, and
that there are two types of parietal thinning of the
skull, flat and grooved. Most cases of parietal thin-
ning are of the flat type (1). Parietal thinning of our
three cases was of the flat type.
As shown by the imaging modalities, the degree
of bone resorption at the external lamina and diploe
of the parietal bone seemed to be greater than at
the internal lamina, resulting in external thinning
of the parietal bones. Seok, et al. (5) observed an
absence of external lamina and diploe of the parie-
tal bones in a patient with parietal thinning, al-
though the internal lamina of the parietal bone was
intact. In case 1, the diploe at the area of depres-
sion of the bilateral parietal bones disappeared. In
case 2, the diploe at the area of depression of the
left parietal bone disappeared, whereas diploe at
the area of depression of the right parietal bone
was preserved. In contrast, in case 3, the diploe was
preserved at the depressed area of the left parietal
bone, although it was not seen at the depressed
area of the right parietal bone.
The anteroposterior and lateral views of 99mTc
MDP bone scintigraphy did not show any changes
in thin parietal bone of our three cases. The de-
gree of radiotracer uptake is thought to depend on
blood flow and rate of bone formation (6, 7). This
result suggests that there are no changes in blood
flow and rate of bone formation in thin parietal
bones of our three cases.
Pretreatment levels of urinary NTX for our three
cases were high compared to the normal range, in-
dicating acceleration of bone resorption. In con-
trast, two of our three cases showed a high level of
serum BAP (Table 2), suggesting high bone turn-
over.
One-year alendronate treatment decreased both
urinary NTX and serum BAP to normal ranges and
increased the whole body BMD of all three pa-
tients, indicating that this treatment improved the
bone mineral metabolism (Fig. 2A-D, Fig. 3A, B).
These results suggest that acceleration of bone re-
sorption is one of the causes of parietal thinning in
osteoporotic patients.
One-year alendronate treatment showed differ-
ent therapeutic effects in the whole body and re-
gional BMDs. The whole body BMD of all patients
increased after treatment. In contrast, the regional
lumbar, femoral, and head BMDs showed differ-
ences in therapeutic benefit (Fig. 2A-D).
At this time, the reasons for excessive bone re-
sorption in the skull, especially in the posterome-
dial part of the parietal bone in osteoporotic pa-
tients, as well as the reasons for enhanced external
lamina bone resorption remain unclear. Further
studies are required to elucidate the biochemical
mechanism of parietal thinning in these patients.
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